INTRODUCTION {#s1}
============

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is characterized by inflammation and destruction of synovial joints leading to progressive joint damage and disability. The etiology of RA is still poorly understood. RA is a multifactorial disorder, involving both genetic and environmental risk factors \[[@R1]\]. Studies indicate that genetic factors may be account for approximately 50--65% of the risk of RA \[[@R2]\]. Human leukocyte antigen (HLA) alleles are well recognized to be implicated in the pathogenesis of RA \[[@R3]\]. Many genome-wide association studies (GWASs) have confirmed known and identified new genetic determinants of RA \[[@R4]\].

The tumor necrosis factor alpha inducible protein 3 (TNFAIP3) gene encodes ubiquitin-editing protein A20 \[[@R5]\]. A20 is a potent anti-inflammatory protein, which is required for the termination of both tumor necrosis factor (TNF) and Toll-like receptor-induced NF-kB signals \[[@R5], [@R6]\]. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity \[[@R7]\].TNFAIP3 could deregulate NF-κB-dependent gene expression via deubiquitinating specific NF-κB signaling molecules \[[@R6]\]. TNFAIP3 gene is located at 6q23, and is reported to be significantly associated with autoimmune diseases, including RA \[[@R8]\]. Recently, a host of studies \[[@R9]--[@R29]\] explored the associations between TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms and RA risk, but with contradictory results. These studies were conflicting and inconclusive due to clinical heterogeneity, different ethnic populations, and small sample sizes. In order to provide a convincing relationship between TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms and RA susceptibility, we performed this comprehensive meta-analysis to clarify the possible associations.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

Selection for eligible studies included in this meta-analysis was presented in Figure [1](#F1){ref-type="fig"}. We yielded a total of 83 citations after initial search. 29 citations were removed after removing duplicates. After screening the titles and abstracts, 27 citations were deleted. 37 citations were selected for further full text review. 16 citations were excluded because they did not conform to the inclusion criteria (see Figure [1](#F1){ref-type="fig"}). We finally identified 21 studies (27,451 cases and 30,443 controls) in this meta-analysis. 14 studies \[[@R9]--[@R13], [@R18], [@R20], [@R21], [@R23], [@R26]--[@R29]\] with 21,040 cases and 23,086 controls examined rs6920220 polymorphism; 6 studies \[[@R14], [@R17], [@R19], [@R22], [@R24], [@R25]\] including 5,912 cases and 6,463 controls investigated rs2230926 polymorphism; 5 studies \[[@R16], [@R18], [@R21], [@R23], [@R24]\] involving 12,518 cases and 14,061 controls explored rs5029937 polymorphism. The characteristics of included studies were summarized in Table [1](#T1){ref-type="table"}. The Newcastle-Ottawa Scale (NOS) scores of all included studies ranged from 5 to 7 stars, suggesting that these studies were of high methodological quality.

![Selection for eligible publications included in this meta-analysis](oncotarget-08-20784-g001){#F1}

###### Characteristics of included studies

  Author and year        Country    Genotype methods   Ethnicity          Case                Control                HWE      NOS
  ---------------------- ---------- ------------------ ------------------ ------ ------ ----- --------- ------ ----- -------- -----
  rs6920220                                                               GG     GA     AA    GG        GA     AA             
  Hegab2016              Egypt      TaqMan             Caucasian          378    15     1     382       15     1     0.0497   6
  Maxwell2012            UK         Unclear            Caucasian          132    123    16    170       86     8     0.465    6
  Ben Hamad2012          Tunisia    TaqMan             Tunisian           77     56     8     116       65     10    0.820    7
  Hughes2010             USA        PCR                African-American   450    100    6     626       155    10    0.908    6
  Morgan2010             UK         PCR                Caucasian          464    303    43    2146      1197   135   0.045    5
  Plant2010              Mixed      PCR                Caucasian          1963   1044   139   2538      1349   179   0.988    7
  Han2009                Korea      Unclear            Asian              1307   5      0     962       13     0     0.834    6
  Stark2009              Slovak     PCR                Caucasian          324    175    16    213       78     7     0.964    6
  Orozco2009             UK         PCR                Caucasian          2173   1449   221   2143      1188   136   0.070    7
  Dieguez-Gonzalez2009   Spain      PCR                Caucasian          1004   567    80    1034      520    65    0.970    6
  Perdigones2009         Spain      TaqMan             Caucasian          391    204    30    421       197    24    0.873    6
  Lee2009                Korea      PCR                Asian              1110   3      0     986       1      0     0.987    6
  Thomson2007            UK         PCR                Caucasian          2713   1816   277   2287      1266   142   0.041    6
  Burton2007             UK         TaqMan             Caucasian          1007   723    127   1757      1049   129   0.078    6
  rs2230926                                                               TT     TG     GG    TT        TG     TT             
  Hao2014                China      TaqMan             Asian              170    34     3     184       13     2     0.005    7
  Zhang2014              China      TaqMan             Asian              1072   200    8     1133      143    4     0.819    5
  Kim2014                Korea      Unclear            Asian              364    52     0     367       45     0     0.241    6
  Perkins2012            USA        TaqMan             African American   177    208    61    282       345    106   0.977    7
  Musone2011             USA        Unclear            Caucasian          133    14     1     1430      82     1     0.874    6
  Shimane2010            Japan      Unclear            Asian              2815   571    29    2016      299    11    0.981    6
  rs5029937                                                               GG     GT     TT    GG        GT     TT             
  Vernerova2016          Slovakia   TaqMan             Caucasian          477    21     1     850       43     1     0.554    6
  Kim2014                Korea      Unclear            Asian              364    54     1     379       43     0     0.270    7
  Maxwell2012            UK         Unclear            Caucasian          227    29     0     236       18     0     0.558    5
  Plant2010              Mixed      PCR                Caucasian          6977   735    19    8847      547    9     0.856    6
  Orozco2009             UK         PCR                Caucasian          3291   309    13    2876      207    5     0.528    6

HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa Scale

Associations of the TNFAIP3 gene polymorphisms with RA susceptibility {#s2_2}
---------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, we found a significant association between TNFAIP3 gene rs6920220 (AA vs. GA+GG: OR, 1.36; 95% CI, 1.24--1.50, *P* \< 0.001, Figure [2](#F2){ref-type="fig"}), rs2230926 (TG+GG vs. TT: OR, 1.39; 95% CI, 1.11--1.72, *P* = 0.003, Figure [3](#F3){ref-type="fig"}), and rs5029937 (T vs. G: OR, 1.42; 95% CI, 1.17--1.73, *P* \< 0.001, Figure [4](#F4){ref-type="fig"}) polymorphisms with the increased risk of RA. Stratification analysis of ethnicity indicated that rs6920220 and rs5029937 polymorphisms increased the risk of RA among Caucasians, while rs2230926 polymorphism among increased the risk of RA among Asians. Similar results were obtained among all included studies when conducted stratification analysis of HWE status (Table [3](#T3){ref-type="table"}).

###### Meta-analysis of association between TNFAIP3 rs6920220, rs5029937 and rs2230926 polymorphisms and RA risk

  Comparison      OR(95%CI)             *P*-value   P for heterogeneity   I^2^ (%)   Model
  --------------- --------------------- ----------- --------------------- ---------- --------
  **rs6920220**                                                                      
  A vs. G         **1.17(1.08,1.26)**   \< 0.001    \< 0.001              67.3       Random
  GA+AA vs. GG    **1.19(1.09,1.29)**   \< 0.001    \< 0.001              65.2       Random
  AA vs. GA+GG    **1.36(1.24,1.50)**   \< 0.001    0.312                 13.5       Fixed
  **rs5029937**                                                                      
  T vs. G         **1.42(1.17,1.73)**   \< 0.001    0.038                 60.6       Random
  GT+TT vs. GG    **1.42(1.15,1.75)**   0.001       0.028                 63.2       Random
  TT vs. GT+GG    **2.40(1.30,4.44)**   0.005       0.955                 0.0        Fixed
  **rs2230926**                                                                      
  G vs. T         **1.37(1.10,1.71)**   0.005       0.001                 75.7       Random
  TG+GG vs. TT    **1.39(1.11,1.72)**   0.003       0.009                 67.6       Random
  GG vs. TT+TG    1.14(0.86,1.52)       0.358       0.180                 36.2       Fixed

^\*^Bold values are statistically significant (P \< 0.05).

![Forest plot shows odds ratio for the associations between rs6920220 polymorphism and RA risk (AA vs. GA+GG)](oncotarget-08-20784-g002){#F2}

![Forest plot shows odds ratio for the associations between rs2230926 polymorphism and RA risk (TG+GG vs. TT)](oncotarget-08-20784-g003){#F3}

![Forest plot shows odds ratio for the associations between rs5029937 polymorphism and RA risk (T vs. G)](oncotarget-08-20784-g004){#F4}

###### Summary of the subgroup analyses in this meta-analysis

  Comparison      Category     Category            Studies   OR (95% CI)           *P*-value
  --------------- ------------ ------------------- --------- --------------------- -----------
  **rs6920220**                                                                    
  A vs. G         Ethnicity    Caucasian           10        **1.19(1.11,1.28)**   \< 0.001
                               Tunisian            1         1.20(0.84,1.72)       0.326
                               African--American   1         0.90(0.70,1.16)       0.412
                               Asian               2         0.69(0.08,5.89)       0.733
                  HWE status   negative            3         **1.22(1.14,1.30)**   \< 0.001
                               positive            11        **1.16(1.05,1.28)**   0.004
  GA+AA vs. GG    Ethnicity    Caucasian           10        **1.21(1.12,1.31)**   \< 0.001
                               Tunisian            1         1.29(0.83,2.00)       0.264
                               African--American   1         0.89(0.68,1.17)       0.419
                               Asian               2         0.69(0.08,5.92)       0.733
                  HWE status   negative            3         **1.24(1.15,1.33)**   \< 0.001
                               positive            11        **1.18(1.05,1.32)**   0.005
  AA vs. GA+GG    Ethnicity    Caucasian           10        **1.37(1.24,1.51)**   \< 0.001
                               Tunisian            1         1.09(0.42,2.83)       0.862
                               African--American   1         0.85(0.31,2.36)       0.758
                  HWE status   negative            3         **1.49(1.25,1.78)**   \< 0.001
                               positive            9         **1.31(1.17,1.47)**   \< 0.001
  **rs2230926**                                                                    
  G vs. T         Ethnicity    Asian               4         **1.42(1.21,1.67)**   \< 0.001
                               African--American   1         0.96(0.81,1.14)       0.627
                               Caucasian           1         **2.00(1.16,3.46)**   0.013
                  HWE status   negative            1         **2.40(1.34,4.30)**   0.003
                               positive            5         **1.29(1.04,1.60)**   0.020
  TG+GG vs. TT    Ethnicity    Asian               4         **1.45(1.21,1.74)**   \< 0.001
                               African--American   1         0.95(0.75,1.21)       0.678
                               Caucasian           1         **1.94(1.09,3.46)**   0.024
                  HWE status   negative            1         **2.67(1.41,5.04)**   0.002
                               positive            5         **1.30(1.07,1.59)**   0.010
  GG vs. TT+TG    Ethnicity    Asian               3         **1.81(1.02,3.20)**   0.042
                               African--American   1         0.94(0.67,1.32)       0.708
                               Caucasian           1         10.29(0.64,165.29)    0.100
                  HWE status   negative            1         1.45(0.24,8.76)       0.687
                               positive            4         1.47(0.80, 2.70)      0.220
  **rs5029937**                                                                    
  T vs. G         Ethnicity    Caucasian           4         **1.43(1.14,1.79)**   0.002
                               Asian               1         1.33(0.89,2.01)       0.168
  GT+TT vs. GG    Ethnicity    Caucasian           4         **1.43(1.12,1.82)**   0.004
                               Asian               1         1.33(0.87,2.04)       0.185

^\*^Bold values are statistically significant (*P* \< 0.05)

We assessed sensitivity by omitting each study once at a time in every genetic model for the three polymorphisms. This meta-analysis indicated that the data of these three single nucleotide polymorphisms (SNPs) (rs6920220, GA+AA vs. GG, Figure [5](#F5){ref-type="fig"}) were stable and trustworthy. Both Egger\'s and Begg\'s tests (rs6920220, AA vs. GA+GG, Figure [6](#F6){ref-type="fig"}) were used to evaluated the publication bias of this meta-analysis. Our data revealed that there was no obvious publication bias for above polymorphisms (data not shown).

![Sensitivity analyses for the associations between rs6920220 polymorphism and RA risk (GA+AA vs. GG)](oncotarget-08-20784-g005){#F5}

![Begg\'s tests between rs6920220 polymorphism and RA risk (AA vs. GA+GG)](oncotarget-08-20784-g006){#F6}

DISCUSSION {#s3}
==========

In this meta-analysis, our data found that TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms increased the risk of RA. Stratification analysis of ethnicity indicated that rs6920220 and rs5029937 polymorphisms increased the risk of RA among Caucasians, while rs2230926 polymorphism among increased the risk of RA among Asians.

TNFAIP3 is an inhibitor of the NF-κB signaling pathway, which is significantly associated with the development of RA \[[@R30]\]. Vereecke et al. illustrated the importance of TNFAIP3 in the resolution of inflammation and the prevention of RA \[[@R31]\]. TNFAIP3 gene involves in the negative regulation of inflammatory responses, and alters the expression or activity of A20, which influence the pathogenesis of RA \[[@R7]\]. A meta-analysis performed by Lee et al. investigated TNFAIP3 gene rs6920220, rs2230926 polymorphisms with RA susceptibility recently \[[@R32]\]. They found that rs6920220 and rs2230926 polymorphisms were associated with the increased risk of RA, which is consistent with our results. The findings of this present meta-analysis regarding the association between rs6920220, rs2230926 polymorphisms and RA in Caucasians and Asians are mostly in agreement with the previous meta-analysis by Lee et al.y \[[@R32]\]. However, our data showed no association of rs2230926 polymorphism with RA in African--Americans, unlike the positive result from Lee et al. \[[@R32]\]. Furthermore, our data about rs2230926 polymorphism among African--Americans was also in accordance with findings of original study by Perkins et al. from America \[[@R19]\], indicating that the data of Lee et al. was not trustworthy. We also found rs2230926 polymorphism was associated with the risk of RA among Caucasians, which was not uncovered by previous meta-analysis \[[@R32]\]. Another notable limitation of the meta-analysis by Lee et al. was that they did not include several studies of rs6920220 polymorphism \[[@R11], [@R15], [@R18], [@R20], [@R21], [@R28]\], which actually met the inclusion criteria of their meta-analysis. Therefore, we assumed previous meta-analysis could not provide a comprehensive conclusion. Furthermore, Additional studies \[[@R9], [@R14], [@R23]--[@R25]\] have been published in recent years since the meta-analysis. The findings of these studies were conflicting. Distribution of gene functional polymorphisms varying in different races, inadequate statistical power of single study, clinical heterogeneity, small sample size, or uncorrected multiple hypothesis testing may contribute to the inconsistent findings. In order to overcome these limitations, it is necessary to conduct a new meta-analysis including the updated data to confirm whether the TNFAIP3 gene polymorphisms are associated with RA susceptibility.

We believe our meta-analysis has some strengths over previous meta-analysis Lee et al. for the following reasons. First, we included 14 studies with 21,040 cases and 23,086 controls examining rs6920220 polymorphism and 6 studies with 5,912 cases and 6,463 controls investigating rs2230926 polymorphism, indicating that the sample sizes of rs6920220 and rs2230926 polymorphisms were large. Second, we conducted sensitivity analysis and power analysis, suggesting that our data about these SNPs were trustworthy and robust. Third, we also conducted a meta-analysis of another SNP of TNFAIP3 gene (rs5029937 polymorphism). The data revealed that rs5029937 polymorphism increased the risk of RA. Stratification analysis of ethnicity also found a positive association between rs5029937 polymorphism and RA among Caucasians, but not Asians. There are several possible interpretations for different results of these SNPs between Asians and Caucasians. First, genetic heterogeneity for RA may exist in different populations. Second, the discrepancy may be explained by clinical heterogeneity between the different populations. Third, the sample sizes of the Asian populations might not have been sufficiently large to reach a convincing conclusion when compared with Caucasian populations. Additionally, the different genotyping methods and random errors may also been potential reasons for different findings between Asians and Caucasians. To our knowledge, this is the first meta-analysis to address the association between rs5029937 polymorphism and RA risk.

Several potential limitations should be addressed in this meta-analysis. First, due to limited data, we could not perform further stratification analyses of other potential factors, such as rheumatoid factor (RF). Second, our results were based on unadjusted estimates for confounding factors, which might have affected the final conclusions. Third, we could not assess potential gene-gene and gene-environment interactions due to the lack of relevant data. Fourth, we cannot examine the associations between these SNPs of TNFAIP3 and the clinical manifestations of RA. Fifth, some genetic models of this meta-analysis were high, and it is necessary to interpret it with caution. Sixth, the sample sizes of stratification analyses were limited.

In conclusion, this meta-analysis indicates that TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms are associated with the increased risk of RA. Stratification analysis of ethnicity reveals that rs6920220 and rs5029937 polymorphisms increase the risk of RA among Caucasians, while rs2230926 polymorphism increases the risk of RA among Asians. Further studies are required to determine whether these SNPs of TNFAIP3 gene contribute to RA susceptibility in different ethnic groups.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We systematically searched the PubMed and Embase to identify studies through September 16, 2016. The following search terms were used: "tumor necrosis factor alpha inducible protein 3," ''TNFAIP3,'' ''A20,'' ''Rheumatoid Arthritis,'' ''RA,'' ''polymorphism,'' ''SNP'' and ''polymorphisms''. No restrictions were placed on the search. Additional initially omitted studies (such as reference lists of identified studies) have been identified by hand screening. The identified studies conformed to the following criteria: studies that evaluated the association between RA risk and TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms, study provided sufficient data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs), and *P* value, and case-control study. Exclusion criteria were: duplication of previous studies; review, or other non-original studies; studies without detailed genotype data.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Relevant information was carefully extracted from all eligible studies. The extracted information from all eligible studies included: name of first author, publication year, country of origin, genotype methods, ethnicity, and genotype numbers of cases and controls. Two reviewers independently performed the extraction of data and assessed the study quality based on the NOS \[[@R33]\]. All disagreements were discussed and resolved with consensus.

Statistical analysis {#s4_3}
--------------------

All statistical analyses were performed using the Stata 11.0 software (StataCorp, College Station, TX, USA). ORs and 95%CIs were used to assess the strength of associations between TNFAIP3 gene rs6920220, rs2230926, and rs5029937 polymorphisms and RA risk. Stratification analyses were carried out by ethnicity and HWE status. When a Q test indicated *P* \< 0.1 or I^2^ \> 50% indicated heterogeneity across studies, a random-effect model was used. Otherwise, the fixed-effects model was applied \[[@R34]\]. Pooled ORs were calculated for allele model, dominant model, and recessive model. We performed sensitivity analyses by omitting each study in turn to determine the effect on the test of heterogeneity and evaluated the stability of the overall results. We assessed the departure from the HWE in the controls using Pearson\'s χ^2^ test. Potential publication bias was assessed by Begger\'s and Egger\'s linear regression test \[[@R35]\]; *P* \< 0.05 was considered to indicate statistically significant. The power of this meta-analysis was calculated with a significant value of 0.05 \[[@R36]\].

This work supported by the National Natural and Science Foundation (81501874) and Jiangsu Province Health and Family Planning Commission Foundation (Q201511).

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

RA

:   rheumatoid arthritis

RF

:   rheumatoid factor

TNFAIP3

:   tumor necrosis factor alpha inducible protein 3

GWAS

:   genome-wide association study

HLA

:   Human leukocyte antigen

HWE

:   Hardy--Weinberg equilibrium

CI

:   confidence interval

OR

:   odds ratio

NOS

:   Newcastle-Ottawa Scale

SNP

:   single nucleotide polymorphism

[^1]: Co-first author
